Azeemuddin Mohammed, Anturlikar Suryakanth D, Onkaramurthy Mallappa, Baig Mirza R, Ashok Basti K, Rao Raghavendra P, Rafiq Mohamed, Rangesh Paramesh
Discovery Sciences Group, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.
Department of Microbiology & Toxicology R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.
Adv Pharmacol Sci. 2019 Feb 3;2019:8272850. doi: 10.1155/2019/8272850. eCollection 2019.
The objective of the present study was to evaluate "DXB-2030," a polyherbal combination of , , , , and extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary syndrome (PCOS) in female rats. Thirty animals were divided into 3 groups of 10 each; group 1 served as normal control; group 2 was administered with TP and served as positive control; along with TP, group 3 was treated with "DXB-2030" at a dose of 100 mg/kg p.o., for 60 days. At the end of the study period, the animals were subjected for the estimation of serum testosterone levels, oral glucose tolerance test (OGTT), weight of the ovaries, estrous cycle, and histopathological evaluation. An in vitro assay on GLUT4 expression was carried out to understand the effect of "DXB-2030" on insulin resistance. Results showed that treatment with "DXB-2030" reversed the TP-induced changes by increasing the GLUT4 expression and decreasing the body weight, testosterone levels, AUC of glucose in OGTT, and the cystic follicles of the ovaries, thus indicating its beneficial effect in PCOS by ameliorating the metabolic dysfunction and reproductive impairment, which are the pathophysiological conditions associated with PCOS. From the results obtained, it can be concluded that "DXB-2030" was effective in the management of experimental PCOS and hence may be recommended in the treatment of PCOS.
本研究的目的是在丙酸睾酮（TP）诱导的雌性大鼠多囊卵巢综合征（PCOS）实验模型中，评估“DXB - 2030”，一种由[具体植物提取物1]、[具体植物提取物2]、[具体植物提取物3]、[具体植物提取物4]和[具体植物提取物5]提取物组成的多草药组合物。将30只动物分为3组，每组10只；第1组作为正常对照组；第2组给予TP并作为阳性对照组；第3组在给予TP的同时，以100 mg/kg口服剂量给予“DXB - 2030”，持续60天。在研究期结束时，对动物进行血清睾酮水平测定、口服葡萄糖耐量试验（OGTT）、卵巢重量、发情周期和组织病理学评估。进行了关于GLUT4表达的体外试验，以了解“DXB - 2030”对胰岛素抵抗的影响。结果表明，“DXB - 2030”治疗通过增加GLUT4表达、降低体重、睾酮水平、OGTT中葡萄糖的AUC以及卵巢的囊性卵泡，逆转了TP诱导的变化，从而表明其通过改善代谢功能障碍和生殖损伤（这些是与PCOS相关的病理生理状况）对PCOS具有有益作用。从获得的结果可以得出结论，“DXB - 2030”在实验性PCOS的管理中有效，因此可能推荐用于PCOS的治疗。
